Refractory PAs lie between benign adenomas and true malignant PC and are defined as aggressive-invasive PAs characterized by a high Ki-67 index, rapid growth, frequent recurrence, and resistance to conventional treatments, including temozolomide (TMZ) (10, 11). This evidence concerns the gene MKI67 and pachyonychia congenita.